Why is LBRX up?
Up 124% since it listed in Sep 2025 while the S&P 500 rose 17%.
- Its 5 peers' median return since Sep 2025 was +100%,
The timeline and its peers, for Pro members.
LB Pharmaceuticals (LBRX) stock
$39.34
Quality Score
5
In its industry
#70of 291
LBRX's Quality Score rose 2 points on Mon, Oct 26, to 5. Buying volume reached a 20-day high (2 chart checks started).
Follow LBRX's trial news. Pro members can get an alert when LB Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
Get an alert when LBRX files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
NextEarly 2027“Initiation of the Phase 2 trial in the adjunctive treatment of MDD is expected in early 2027…”
Key facts on LBRX
| Holding it back | An $86M loss |
| Latest filing | S-3ASR, Oct 1 |
4 more reasons behind LBRX's 5, for Pro members.
LBRX catalysts
Coming up
After its last 4 reports it closed -1.1% on average, higher 1 of 4 times.
5 more coming up and 10 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →
What's next for LBRX, and how long its cash lasts
Next step the company has named
Early 2027“Initiation of the Phase 2 trial in the adjunctive treatment of MDD is expected in early 2027, with topline data”
Cash runway
The company says its cash lasts beyond Q2 2029 (8-K, Aug 11).
Dilution on the horizon
No shelf registration or at-the-market program on file in the last three years.
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
DateStockDrug
- In 15 days
NRXPNRX Pharmaceuticals
- In 27 days
CAPRCapricor Therapeutics
- In 27 days
SVRASavara
Why LBRX scores 5
Below AverageTrending up, 4 of 14 chart checks firingWhat the Quality Score means
- +4Chart checks 4 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average
- Run-up adds
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
What every line is worth, and the reason behind it, on LBRX and every other stock.Get in free →
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
LBRX has 4 of 14 chart checks firing
The other 10 checks on LBRX, and all 14 on every stock.Get in free →
LBRX RSI today: 52.1, below its 50-day, above its 200-day
- RSI 1452.1
- MACD (12, 26, 9)Above signal
- 50-day average$42.01
- 200-day average$32.17
- 50/200 crossNo cross
- ADX 1423.8
- Support$33.13
- Resistance$49.14
- 52-week high$50.16
- 52-week low$14.32
- Chart patternNone
- Bollinger Bands (20, 2)Inside
- Volume0.6x
The deep dive on LBRX
- What it does and how it makes moneyIncome statements to Jun 30, 2026, filed Aug 11, 2026
- Where it stands
- Who holds and trades it
4 more findings on LBRX, each with its source, for Pro membersGet in free →
How LBRX ranks in Biotech
LBRX is #70 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 70 |
When does LBRX report earnings, and what happens after?
Expected to report Thu Nov 12, before the open (in 17 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What LBRX reported on Aug 11, 2026
The quarter
The figures are not read from the release yet.
“The increase of $41.7 million was primarily due to (i) a $32.1 million increase in expenses primarily related to our Phase 3 clinical trial of LB-102 in the treatment of patients with acute schizophrenia; (ii) a $2.7 million increase in expenses related to the conduct of our Phase 2 clinical trial of LB-102 in the treatment of patients with bipolar depression; (iii) a $2.0 million increase in expenses related to the formulation and production of LB-102 for use in our active and planned clinical trials; (iv) a $4.0 million increase in personnel-related expenses primarily due to an increase in headcount, an increase in termination benefits, and an increase in stock compensation expense related to an option modification; and (v) a $1.3 million increase in preclinical and other direct expenses related to LB-102.”
Where the sales came from
LBRX's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“The increase of $7.3 million was primarily due to (i) a $2.8 million increase in stock-based compensation expense primarily related to stock options granted and repriced in connection with the IPO, new hire grants, and an option modification; (ii) a $2.3 million increase in professional, consulting and public company related expenses; and (iii) a $2.1 million increase in personnel-related expenses primarily due to an increase in headcount.”
From its results filing (SEC filing · Aug 11)
The numbers
- $1.3B
- today
- -$82.8M
- last 12 months
The whole report on LBRX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 11, 2026 | +0.2% | -1.1% | +0.8% |
| May 12, 2026 | -1.1% | +3.8% | -12.4% |
| Mar 26, 2026 | +1.7% | -2.8% | +4.7% |
Which ETFs hold LBRX?
In ETFs: LBRX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About LB Pharmaceuticals
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
LBRX's score card
Pro members see every line of every stock's score.
- What would turn LBRX's score around: 6 things
- 12 more filings explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is LBRX a good stock to buy? What its Quality Score says
LBRX scores 5 today, which Breakaway calls Below Average. It is #70 of 291 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 124% since it listed in Sep 2025 while the S&P 500 rose 17%. Shares: 84.0 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is LBRX's Quality Score?
LBRX scores 5 today, which Breakaway calls Below Average (0 to 5). That is #70 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LBRX's 5.
When does LBRX report earnings?
Expected to report Thu Nov 12, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. LBRX closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.